摘要
本文报道常量顺铂(DDP)作为鼻咽癌放疗前的诱导治疗,放疗中增敏、放疗后巩固疗效及复发病的治疗共145人,241例次。治疗主要采用PO方案(DDP20mg,静滴,1次/日,连用5天,VCR1—1.5mg,第1,5天)。结果:放疗前诱导治疗70例,PR 22.8％,复发治疗28例,PR21.4％。增敏治疗39例,可评价21例,增敏患者肿块缩小达CR的最低放疗量平均为28.25Gy,而对照组(单用放疗)为35.4Gy,但统计学上无显著差异。采用本化疗方案,17.4％的病例无任何毒副反应,82.6％有不同程度的消化道反应,对血象及肝、肾功能均无明显影响 本例研究表明,顺铂在鼻咽癌诱导缓解及抗复发治疗中有肯定效果,增敏及巩固治疗的作用也值得进一步研究。
In this paper 145 cases with nasopharyngeal carcinoma (NPC) treated by low dose Cis-platinum(LD-CDDP) and vincristin (DDP 20 mg ivd q.d, VCR 1.5 mg iv 1, 5d) were reported. Seventy patients were treated by one course of PO regimen before radiotherapy, the PR was 22.8%. Twenty-eight patients were treated by this regimen for recurrence of NPC, the PR was 21.4%. Thirty nine patients were treated by this schedue for radiosensitization Twenty- one cases were evaluable, the lowest mean dose of tumor which arrived to CR was 28.25 Gy in the trial group and 35.4 Gy in the radiotherapy alone group. There are 7.15 Gy decreased in the radiosensitization group as compared to the radiotherapy alone group. The side-effects were acceptable. 83.6% of patient with complaint of anorexia and nausea.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
1989年第2期109-112,共4页
Chinese Journal of Cancer
